Q4 FY2024 · ended Dec 31, 2024 · Revenue $4.39M, -63.9% YoY · Filed Mar 25, 2026
Equillium, Inc. (EQ) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$4.2 million. As of Jun 30, 2026 it held $57.2 million in cash and investments and $584,000 in total debt.
Revenue
$4.39M
-63.9% vs prior quarter
Net income
$-4.69M
+18.2% vs year-ago quarter
Operating cash flow
$-4.11M
-36.3% vs year-ago quarter
Free cash flow
$-4.18M
-38.7% vs year-ago quarter
EPS
$-0.04
+75.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
63.41M
+6.6% vs year-ago quarter
Net cash
$56.58M
Q2 FY2026
Operating margin
-107.0%
Q4 FY2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EQ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1746466
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.2M | -$5.6M | -$4.0M | -$4.6M | -$6.2M |
| Net income | -$4.7M | -$5.3M | -$3.8M | -$4.2M | -$5.7M |
| Diluted EPS | -$0.04 | -$0.06 | -$0.04 | -$0.06 | -$0.16 |
| Operating cash flow | -$4.1M | -$4.3M | -$3.1M | -$8.4M | -$3.0M |
| Free cash flow | -$4.2M | -$4.3M | -$3.2M | -$8.4M | -$3.0M |
| Total assets | $58.7M | $63.1M | $31.9M | $34.5M | $12.4M |
| Total liabilities | $2.6M | $3.6M | $3.3M | $3.6M | $7.3M |
| Stockholders' equity | $56.0M | $59.5M | $28.6M | $30.9M | $5.1M |
| Cash and investments | $57.2M | $61.3M | $30.3M | $33.1M | $11.5M |
| Total debt | $584,000 | $692,000 | $719,000 | $745,000 | $259,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Unregistered share sale, Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 465 Equillium, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.